Research Article
HDAC Inhibitors as Anticancer Therapeutics
Sidra Shafique*
Department of Reproduction and Developmental Sciences DBMS, Queen’s University Kingston, Canada
Sidra Shafique, Reproduction and Developmental Sciences DBMS, Queen’s University Kingston, Canada.
Received Date:September 13, 2018; Published Date: October 04, 2018
Abstract
Underlying mechanisms of carcinogenic aberrations in genome stems from genetic mutations and epigenetic modulations followed by a cascade of mechanistic events in signaling pathways. Acetylation status have been identified as one of the key markers of cancerous cells along with the over expression of Histone deacetylases (HDACs). In this context, HDACs are the focus of cancer research both from the cause and the treatment perspectives. HDAC inhibitors are one of the time-tested therapeutics and have recently been used as an effective adjuvant with the combination therapeutic regimens of cancers such as breast cancer. Here, we discuss the HDAC inhibitors as cancer treatment option in context with carcinogenic role of epigenetic modifications.
-
Sidra Shafique. HDAC Inhibitors as Anticancer Therapeutics. Arch Phar & Pharmacol Res. 1(2): 2018. APPR. MS.ID.000508.